The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

The agency will now require randomized, controlled data before approving new COVID shots for healthy children and adults, ...

4 1. FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or ...

“We want to create a framework for vaccine makers that they can use so they have a predictable FDA where they don’t have to worry how is this going to be received.” The FDA is a massive ...

FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients ...

"Without trials, it is only a matter of time before the FDA approves a vaccine that causes some bad outcome like vaccine-induced narcolepsy. If this happens, you can kiss faith in vaccines goodbye.

But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications.

Sanofi expands its U.S. manufacturing with a $20 billion investment. The FDA approves Merck's cancer drug for rare adrenal ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced ...

FDA approved Merck's Welireg as the first oral therapy for advanced pheochromocytoma or paraganglioma (PPGL). In the LITESPARK-015 trial, Welireg showed a 26% ORR and a 20.4-month median duration ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, ...